GlobeNewswire Clinical StudiesOriginal article
LEQEMBI® Real-World LEADER Study Presented at AAIC® 2026 Finds Over 75% of Early Alzheimer’s Patients Enrolled in the Study Remained Stable and Nearly 7% Improved Over an Average of 17 Months of Treatment
Data ReadoutpositiveLEQEMBIPositive
AI Analysis
Summary
Real-world LEADER study data presented at AAIC 2026 demonstrates that over 75% of early Alzheimer's patients treated with LEQEMBI remained stable and nearly 7% improved over an average of 17 months, supporting long-term benefits of continuous treatment outside of controlled clinical trial settings.
Clinical Trial Data
Primary Endpoint
Met
Outcome Details
Real-world LEADER study presented at AAIC 2026 showing over 75% of early Alzheimer's patients remained stable and nearly 7% improved over average 17 months of treatment
Importance:6/10
Sentiment:
0.75
real-world dataAlzheimer's diseaseLEQEMBIAAIC conferencetreatment stabilitylong-term outcomes
Related Companies
Read the original article
Published by GlobeNewswire Clinical Studies on July 14, 2026 3:18 PM